|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.5 HKD | +0.83% |
|
+10.11% | -18.56% |
| Apr. 26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
RemeGen Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 1,083 million compared to CNY 772.11 million a year ago. Net loss was CNY 1,540.09 million compared to CNY 998.83 million a year ago.
Basic loss per share from continuing operations was CNY 2.86 compared to CNY 1.88 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.56% | 3.48B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
REMEGEN CO., LTD. 
